GlassScriptPhysician profile
Lorraine M Wonner
NPI 1518269661
$2,653.04
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $804 · 2022: $1,089 · 2023: $747 · 2024: $13.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $759.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $323.67 | 2021-2023 | |
| Astellas Pharma US INC | $222.96 | 2021-2024 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $215.74 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $192.66 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $178.17 | 2021-2023 | Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $178.00 | 2022-2023 | |
| Glaxosmithkline, LLC. | $152.20 | 2021-2023 | Trelegy Ellipta, Shingrix, Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.57 | 2022-2023 | Trulance, Xifaxan |
| Pfizer INC. | $116.63 | 2021-2023 | |
| Lilly USA, LLC | $102.01 | 2021-2023 | Mounjaro, Jardiance |
| Amgen INC. | $89.80 | 2022-2023 | Prolia, Evenity |
| Sanofi Pasteur INC. | $76.54 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.62 | 2021-2023 | Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $59.66 | 2022-2023 | Xarelto |
| Sunovion Pharmaceuticals INC. | $57.77 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $54.22 | 2021-2023 | Vaxneuvance, Gardasil 9, Vaqta |
| Novo Nordisk INC | $53.35 | 2021-2023 | Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $44.88 | 2021 | |
| Amarin Pharma, INC. | $38.41 | 2021 | |
| Sumitomo Pharma America, INC. | $35.10 | 2023 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $31.46 | 2022 | |
| Abbott Laboratories | $29.39 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $28.20 | 2021-2022 | |
| Edwards Lifesciences Corporation | $28.07 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $21.55 | 2022 | |
| Exact Sciences Corporation | $20.26 | 2023 | Cologuard Collection Kit |
| Biogen, INC. | $18.21 | 2021 | |
| Corcept Therapeutics | $16.07 | 2022 | |
| Seqirus USA INC | $14.98 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Avanir Pharmaceuticals, INC. | $14.93 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.83 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.75 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorraine Wonner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.